BioXcel IGALMI sNDA Accepted for At-Home Acute Agitation with Nov.14 PDUFA Date
FDA accepted BioXcel’s supplemental NDA for IGALMI to treat acute agitation in bipolar disorders and schizophrenia at home, assigning a Nov. 14, 2026 PDUFA target action date. The at-home indication could address up to 86 million annual agitation episodes lacking approved outpatient options.
1. FDA Acceptance of Supplemental NDA
BioXcel received FDA acceptance of its supplemental New Drug Application for IGALMI to enable at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. This regulatory milestone follows the original sublingual film approval and expands the drug’s therapeutic scope beyond supervised settings.
2. At-Home Treatment Scope and Market Potential
The at-home indication aims to tackle up to 86 million annual agitation episodes among adults with bipolar I or II disorder or schizophrenia, representing the first potential outpatient option for these neuropsychiatric crises. The broader access could reduce emergency department visits and hospitalization costs for caregivers and health systems.
3. Regulatory Timeline
The FDA assigned a Prescription Drug User Fee Act target action date of November 14, 2026 for the sNDA review. BioXcel will engage with regulators on any additional data requests and prepare for potential label revisions ahead of the decision.
4. Commercial Strategy
Following acceptance, BioXcel plans to refine its go-to-market approach, develop patient and provider education materials, and establish distribution channels. The company aims to collaborate with healthcare networks and pharmacies to support outpatient administration protocols upon approval.